Harrington, Kevin

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 5,101

The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence

Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer

Cancer Cells and MetastasisEffects of Radiation Exposure

Cited by 2,144

Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells

Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., & Sahai, E. (2007) · Nature Cell Biology

Cellular Mechanics and InteractionsProtein Kinase Regulation and GTPase Signaling

Cited by 1,589

Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts

Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology

Hippo pathway signaling and YAP/TAZCellular Mechanics and Interactions

Cited by 1,478

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Lee, N. Y., Ferris, R. L., Psyrri, A., Haddad, R. I., Tahara, M., Bourhis, J., Harrington, K., Chang, P. M.-H., Lin, J.-C., Razaq, M. A., et al. (2021) · The Lancet Oncology

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 661

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 592

Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I., & Galluzzi, L. (2020) · Nature Immunology

Cancer Immunotherapy and BiomarkersCell death mechanisms and regulation

Cited by 385

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

Harrington, K. J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., & Golan, T. (2018) · Annals of Oncology

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 280

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Ho, A. L., Brana, I., Haddad, R., Bauman, J., Bible, K., Oosting, S., Wong, D. J., Ahn, M.-J., Boni, V., Even, C., et al. (2021) · Journal of Clinical Oncology

Head and Neck Cancer StudiesLung Cancer Treatments and Mutations

Cited by 208

Oncolytic virotherapy as immunotherapy

Melcher, A., Harrington, K., & Vile, R. (2021) · Science

Virus-based gene therapy researchImmunotherapy and Immune Responses

Cited by 133

STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy

Arwert, E. N., Milford, E. L., Rullan, A., Derzsi, S., Hooper, S., Kato, T., Mansfield, D., Melcher, A., Harrington, K. J., & Sahai, E. (2020) · Nature Cell Biology

interferon and immune responsesVirus-based gene therapy research

Cited by 90

Autocrine IL-1β-TRAF6 signalling promotes squamous cell carcinoma invasion through paracrine TNFα signalling to carcinoma-associated fibroblasts

Chaudhry, S. I., Hooper, S., Nye, E., Williamson, P., Harrington, K., & Sahai, E. (2013) · Oncogene

NF-κB Signaling PathwaysTGF-β signaling in diseases

Cited by 43

Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study

Forster, M. D., Dillon, M. T., Kocsis, J., Remenár, É., Pajkos, G., Rolland, F., Greenberg, J., & Harrington, K. J. (2019) · European Journal of Cancer

Head and Neck Cancer StudiesHER2/EGFR in Cancer Research

Cited by 32

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

Dillon, M. T., Grove, L., Newbold, K. L., Shaw, H., Brown, N. F., Mendell, J., Chen, S., Beckman, R. A., Jennings, A., Ricamara, M., et al. (2019) · Clinical Cancer Research

Head and Neck Cancer StudiesHER2/EGFR in Cancer Research

Cited by 16